FHU RedGene
Join Resources To Cure

1ST SCIENTIFIC DAY - October 9, 2026
PROGRAM

From 8:45	**Welcome**
9:20-9:30	**Introduction (Sébastien Maury/Gaëlle Sandillon)**

Session 1: Casgevy, where do we stand?

9:30-9:55	**Gonzalo de Luna & Laure Joseph:** Patients treated with Casgevy in France: where are we?
9:55-10:20	**Anne Hulin:** Individualized busulfan dosing prior to gene therapy
10:20-10:55	**Nicolas Hébert:** Hemolysis markers and cellular distribution of hemoglobins

20mn break

11:15-11:55	**INVITED SPEAKER - Mohsen Alzahrani (Riyadh, Saudi Arabia):** Gene Therapy for Sickle Cell Disease and β-Thalassemia: Real-World Experience, Challenges, and Future Directions

Session 2: Managing the risks (1/2)

11:55-12:20	**Thomas d'Humières:** Managing cardiovascular risks before and after gene therapy or hematopoietic stem cell transplantation
12:20-12:55	**Ivan Sloma:** Monitoring cellular clonality before and after gene therapy or hematopoietic stem cell transplantation

12:55-14:10 Lunch break

Session 2: Managing the risks (2/2)

14:10-14:35	**Mario Amendola:** Monitoring off-target modifications following gene therapy
14:35-15:00	**Julian Boutin:** High-resolution, in-depth assessment of large chromosomal rearrangements at the cleavage site following CRISPR gene therapy for red blood cell disorders
15:00-15:25	**Anne Galy:** Building safer cell and gene therapies

20mn break

Session 3: Therapeutic innovations and future perspectives

15:45-16:10	**Sandrine Visentin and Sarah Szepetowski:** Current standard care for thalassemia major. Role of including allogeneic transplantation.
16:10-16:35	**Bérengère Koehl:** Prospects for treating hemoglobinopathies in pediatrics
16:35-16:45	**Closing remarks**